Evidence map›Paper›PMID 41009862›Full record

ArticleAntibiotics (Basel, Switzerland)2025

1,5-Diarylidene-4-Piperidones as Promising Antifungal Candidates Against

Elise Courvoisier-Dezord, Hugo Ragusa, Axelle Grandé, Louise Denudt, Yolande Charmasson, Frédéric Dumur, Didier Siri, Marc Maresca, Malek Nechab

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elise Courvoisier-DezordAix Marseille Univ, CNRS, Centrale Marseille, iSm2, 13013 Marseille, France.ORCID 0000-0002-4256-3528
Hugo RagusaAix Marseille Univ, CNRS, ICR UMR 7273, F-13397 Marseille, France.
Axelle GrandéAix Marseille Univ, CNRS, Centrale Marseille, iSm2, 13013 Marseille, France.
Louise DenudtAix Marseille Univ, CNRS, Centrale Marseille, iSm2, 13013 Marseille, France.
Yolande CharmassonAix Marseille Univ, CNRS, Centrale Marseille, iSm2, 13013 Marseille, France.
Frédéric DumurAix Marseille Univ, CNRS, Centrale Marseille, iSm2, 13013 Marseille, France.ORCID 0000-0003-4872-094X
Didier SiriAix Marseille Univ, CNRS, ICR UMR 7273, F-13397 Marseille, France.ORCID 0000-0003-1561-7233
Marc MarescaAix Marseille Univ, CNRS, Centrale Marseille, iSm2, 13013 Marseille, France.ORCID 0000-0002-3585-4765
Malek NechabAix Marseille Univ, CNRS, ICR UMR 7273, F-13397 Marseille, France.ORCID 0000-0001-5377-4403

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesThe present study investigates the antifungal potential of 1,5-diarylidene-4-piperidones.

methodsThese compounds were synthesized via Claisen-Schmidt condensation, and their antifungal efficacy was tested against

resultsSystematic modification of the substituent pattern revealed that tetrabutoxy groups exhibited potent activity (MIC of 7.8 µM), surpassing standard antifungals like fluconazole. The selectivity index (SI) values confirmed their safety profile across various human cells. Docking analysis demonstrated that these compounds target sterol 14-demethylase, suggesting potential inhibition of ergosterol synthesis as a mechanism of action. Interestingly, the compounds also demonstrated broad-spectrum activity against other pathogenic yeasts and fungi, including

conclusionsThese findings underscore the potential of 1,5-diarylidene-4-piperidones as promising antifungal candidates with a favorable safety profile.

Indexed as

antifungalCryptococcus neoformanscurcuminspiperidones

Identifiers

PMID41009862
PMCPMC12466757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.